News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The company reported lifetime high EBIDTA of Rs. 250 crores
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
